Senolytic Therapy for Biological Aging
Senolytic Therapy for Biological Aging 2026: The Science, Costs & What You Can Actually Do Now
In 2015, a paper published in Cell described something that sounded more like science fiction than medicine: researchers had identified a class of drugs that could selectively kill senescent cells in living organisms — and doing so reversed measurable signs of ageing, extended healthspan, and in some experiments, extended lifespan. The drugs were called senolytics, and they opened a new chapter in the science of ageing.
In 2026, senolytic research has moved from mouse studies to human clinical trials across multiple conditions. The results are early, promising, and in some cases striking. Commercial products claiming senolytic activity are widely available. And the fundamental question — can clearing senescent cells from the human body meaningfully slow or reverse aspects of biological ageing — is no longer purely theoretical.
This guide explains the science, the current clinical evidence, what is commercially available, the costs, and an honest assessment of what can realistically be done with senolytics in 2026.
What Are Senescent Cells and Why Do They Matter?
The Biology of Cellular Senescence
Every cell in your body has a built-in response to damage, stress, or the accumulation of too many cell divisions: it can enter a state called cellular senescence. A senescent cell is not dead — it is permanently arrested, unable to divide, but metabolically active. It remains in the body and secretes a complex cocktail of inflammatory molecules, proteases, and growth factors collectively called the Senescence-Associated Secretory Phenotype (SASP).
The SASP was originally understood as a tumour suppression mechanism — senescent cells cannot become cancerous (they cannot divide), and they signal to the immune system to clear damaged cells. This is useful in wound healing, embryonic development, and cancer prevention.
The problem emerges with ageing: the immune system's ability to clear senescent cells (immune surveillance) declines with age, and senescent cells accumulate. By middle age, senescent cell burden is measurable in multiple tissues. By older age, senescent cells are present in significant numbers in fat tissue, joints, lung, kidney, liver, brain, and cardiovascular tissue.
The accumulated SASP from these cells creates chronic, low-grade systemic inflammation — inflammaging — that contributes to virtually every age-related disease: cardiovascular disease, diabetes, neurodegeneration, osteoarthritis, osteoporosis, pulmonary fibrosis, and impaired immune function.
What Happens When You Remove Them
The landmark 2011 Baker et al. paper in Nature demonstrated that clearing p16Ink4a-positive senescent cells from transgenic mice delayed the onset of age-related pathologies and extended healthy lifespan. Subsequent studies using pharmacological senolytics reproduced these effects in normal (non-transgenic) aged mice — and the results have been replicated across multiple animal species.
In aged mice, senolytic treatment has produced: improved physical function and grip strength, reduced frailty, improved cardiac function, improved cognitive performance, reduced osteoarthritis severity, improved pulmonary function, and in multiple studies, extension of median lifespan by 25–36%.
The translation of these results to humans is not guaranteed — but the biological mechanisms are highly conserved across species, and the early human data is encouraging.
The First-Generation Senolytic Combination: Dasatinib + Quercetin (D+Q)
The most studied senolytic combination in humans is dasatinib (a tyrosine kinase inhibitor originally approved for leukaemia) combined with quercetin (a naturally occurring plant flavonoid found in capers, apples, and onions).
The combination was identified through computational screening of senescence survival pathways — identifying drugs that block the pro-survival signals that keep senescent cells alive. Dasatinib targets different pathways than quercetin, making the combination more effective than either alone.
Human Clinical Evidence in 2026
Idiopathic Pulmonary Fibrosis (IPF): The first human senolytic trial — published in EBioMedicine in 2019 — enrolled 14 IPF patients treated with intermittent D+Q (3 days on, 3 days off, for 3 weeks). Results showed improvements in physical function measures (6-minute walk distance, chair stands, 4-metre gait speed) compared to baseline. IPF is a fibrotic lung disease with known high senescent cell burden — an ideal initial target.
Diabetic Kidney Disease: A Mayo Clinic trial showed that a single 3-day course of D+Q reduced senescent cell markers in adipose tissue and skin biopsies in patients with diabetic kidney disease, with signals of improved physical function.
Frailty in older adults: Mayo Clinic trials in older adults with physical frailty and chronic kidney disease showed reductions in senescent cell burden (measured in fat tissue biopsies) following D+Q treatment.
Alzheimer's disease (ongoing): The SToMP-AD (Senolytic Therapy to Modulate Progression of Alzheimer's Disease) trial is evaluating D+Q in Alzheimer's patients — rationale based on senescent cell accumulation in the Alzheimer's brain. Results expected 2026–2027.
Important limitation: All published D+Q human trials are small (14–30 patients), short-term, and primarily measure surrogate endpoints (senescent cell markers, functional measures) rather than hard clinical outcomes (mortality, disease progression). Definitive efficacy evidence for longevity benefit in healthy humans does not yet exist.
Fisetin: The Natural Senolytic
Fisetin is a polyphenol found naturally in strawberries, apples, persimmons, and other fruits. It was identified as having senolytic activity in 2018 — showing particular potency against senescent cells in the brain. Fisetin clears senescent cells through multiple pathways and has anti-inflammatory and neuroprotective effects beyond its senolytic activity.
Human evidence: A Mayo Clinic randomised trial published in 2023 (n=40 older adults) found that fisetin supplementation at 20mg/kg (a high dose — approximately 1,400mg for a 70kg adult) for 2 consecutive days per month reduced inflammatory markers and showed signals of improved physical function. Smaller effects than D+Q but with a significantly better safety profile.
Availability: Fisetin is available as a supplement without prescription in the USA and UK. Doses used in clinical research (1,000–1,500mg) are substantially higher than typical commercial supplements (100–500mg). Bioavailability is poor — taking fisetin with a fat-containing meal significantly improves absorption.
Navitoclax (ABT-263): The Next-Generation Senolytic
Navitoclax is a BCL-2/BCL-XL inhibitor — blocking proteins that senescent cells use to survive. It is a potent senolytic in preclinical models, showing dramatic senescent cell clearance and rejuvenation effects in aged mice.
Human development: Navitoclax is being evaluated as a senolytic in human clinical trials — including in combination with JAK inhibitors. However, it causes thrombocytopenia (platelet reduction) as a significant side effect, limiting its use to conditions where the risk-benefit ratio supports it.
Not commercially available for longevity use — this is a research compound in clinical development.
Unity Biotechnology: Clinical-Stage Senolytic Development
Unity Biotechnology (NASDAQ: UBX) is the leading clinical-stage senolytic company in 2026. Their portfolio focuses on:
UBX1325 (foselutoclax): A BCL-2/BCL-XL inhibitor delivered as an intravitreal injection for diabetic macular oedema and neovascular AMD — targeting senescent cells in the retina. Phase 2 data in 2025 showed durable vision improvement. FDA Breakthrough Therapy designation received.
UBX1967: Earlier stage, broader application. The company's pipeline represents the leading edge of senolytic clinical translation.
Costs: USA and UK
Pharmaceutical Senolytics (D+Q Protocol)
Dasatinib (generic available): Prescribed off-label for senolytic use. The intermittent protocol used in clinical research involves 100mg/day for 2–3 days per month.
- USA cost without insurance: approximately $15–$50 per 100mg tablet (generic varies widely by pharmacy)
- UK private prescription: approximately £20–£60 per tablet
- A monthly 2-day course costs approximately $30–$100 in the USA
Quercetin (supplement): Widely available OTC.
- USA: approximately $15–$30/month for 500–1,000mg/day formulation
- UK: approximately £12–£25/month
Total D+Q monthly protocol cost (USA): Approximately $50–$130/month for the intermittent protocol — excluding the physician visit required for dasatinib prescription.
Physician consultation for off-label dasatinib: Longevity medicine physicians willing to prescribe D+Q for senolytic protocols charge $300–$600 for initial consultation; ongoing monitoring visits $150–$300/quarter.
Natural Senolytics (Supplement-Based)
| Supplement | Dose Used in Research | Monthly Cost (USA) | Monthly Cost (UK) |
|---|---|---|---|
| Fisetin | 1,000–1,500mg (2 days/month) | $20–$50 | £15–£40 |
| Quercetin | 500–1,000mg/day | $15–$30 | £12–£25 |
| Luteolin | 100–300mg/day | $20–$40 | £15–£30 |
| Piperlongumine | Research stage | Not standardly available | Not standardly available |
What Can You Actually Do in 2026?
What Has Reasonable Evidence and Is Accessible
Fisetin supplementation (intermittent high-dose): Based on the 2023 Mayo Clinic trial, an intermittent protocol of high-dose fisetin (1,000–1,500mg for 2 consecutive days per month, taken with a fat-containing meal for absorption) has the best evidence-to-safety profile ratio among accessible senolytics. Side effects are minimal. The evidence is early but the risk profile makes it a reasonable option for adults concerned about biological ageing.
Quercetin (daily supplementation): As a standalone intervention and as part of the D+Q combination, quercetin has both senolytic and broad anti-inflammatory effects. Daily supplementation at 500–1,000mg is reasonable and low-risk.
Exercise — the original senolytic: Consistent aerobic exercise has been shown to reduce senescent cell burden and SASP markers in multiple studies — likely through enhanced immune surveillance and mitophagy. The evidence for exercise as a senolytic is in some ways stronger than for any supplement. High-intensity intervals specifically appear to stimulate senescent cell clearance.
What Requires Physician Involvement
Dasatinib: Prescription-only. Requires physician evaluation, baseline blood work (complete blood count, liver function, cardiac evaluation — dasatinib can cause QT prolongation), and monitoring. Not appropriate for self-prescribing.
Navitoclax and pipeline drugs: Clinical trial or specialist centre access only.
What Is Premature for Human Use
Systemic senolytic treatment in healthy young or middle-aged adults has not been tested in clinical trials. The existing human evidence is in older adults (typically 60+) with specific disease states. Extrapolating from diseased elderly populations to healthy middle-aged individuals involves significant assumptions. The longevity medicine community is divided on whether the current evidence supports senolytic use in healthy individuals — conservative practitioners say no; more aggressive longevity physicians say the mechanistic and animal evidence is sufficient to justify cautious clinical use.
Safety Considerations
Dasatinib side effects: Fluid retention, pleural effusion, cardiac arrhythmia (QT prolongation), thrombocytopenia (platelet reduction), neutropenia. The intermittent low-dose protocol used in senolytic research produces fewer adverse effects than the continuous high-dose oncology protocol, but risks are not zero. Contraindicated in patients on certain medications (particularly QT-prolonging drugs) and in those with certain cardiac conditions.
The immune surveillance concern: Senescent cells play important roles in wound healing and tumour suppression. Aggressive senolytic treatment could theoretically impair wound healing or increase cancer risk by eliminating cells that would otherwise become cancerous. Intermittent (not continuous) treatment protocols are designed to allow normal senescence to occur while periodically clearing accumulated burden.
Rapamycin: The mTOR Inhibitor That Has Transformed Longevity Research
No discussion of biological ageing interventions in 2026 is complete without rapamycin (sirolimus) — the compound that has arguably done more than any other to validate the pharmacological targeting of ageing pathways in mammals.
Rapamycin inhibits mTORC1 — the mechanistic target of rapamycin complex 1 — a central regulator of cellular growth, metabolism, protein synthesis, and autophagy. mTOR is chronically overactivated in ageing tissues and in conditions of caloric excess. Inhibiting mTORC1 mimics aspects of caloric restriction — the most consistently lifespan-extending intervention across model organisms.
The lifespan data: Rapamycin is the only drug to date that has consistently extended lifespan across multiple species in controlled laboratory studies — including mice (where it was effective even when started in middle age), yeast, worms, and flies. The Harrison et al. 2009 ITP study showed 9–14% lifespan extension in genetically heterogeneous mice when rapamycin administration began at the equivalent of 60 years of age in humans.
Human use in 2026: Rapamycin is FDA-approved as an immunosuppressant for organ transplant patients and as a treatment for certain tumours. Off-label use for longevity purposes has grown significantly. Many longevity physicians use weekly or biweekly low doses (typically 2–6mg once weekly) rather than the daily continuous dosing used in transplant medicine.
The safety profile at longevity doses: The side effects associated with rapamycin at transplant doses (immunosuppression, impaired wound healing, metabolic effects) are substantially reduced at the intermittent low doses used in longevity protocols. However, rapamycin is not without risk — it requires physician supervision, baseline assessment, and monitoring. It is not appropriate for self-prescribing.
Longevity physicians using rapamycin: Some of the most prominent longevity medicine practitioners in the USA — including Matt Kaeberlein (University of Washington) and a growing number of direct primary care longevity physicians — now include rapamycin in their protocols for selected patients. The Dog Aging Project, studying rapamycin in companion dogs, is providing additional safety and efficacy data with implications for human use.
5 Frequently Asked Questions
Q1: Should I take fisetin supplements for anti-ageing purposes in 2026?
The honest answer is: the evidence is promising but not definitive, the risk profile is low, and a cautious approach is reasonable. If you choose to use fisetin, the protocol showing the most evidence is an intermittent high-dose approach (approximately 1,000–1,500mg for 2 consecutive days per month, taken with food containing fat to improve absorption) rather than daily low-dose supplementation. Discuss with your physician, particularly if you take medications that could interact with flavonoids.
Q2: Can I get D+Q prescribed in the UK?
Dasatinib is a licensed medicine in the UK (for leukaemia). Off-label prescribing for senolytic purposes is legal but not common — you would need a physician willing to prescribe off-label with appropriate monitoring. Private longevity medicine physicians in London (at clinics listed in our Longevity Clinics article) are the most likely source for an off-label dasatinib prescription with proper clinical oversight. NHS prescribing for off-label senolytic use is not available.
Q3: How would I know if senolytics are working for me?
Measuring senolytic efficacy in individuals is challenging because the primary outcomes in clinical trials are tissue biopsies (measuring p16, p21, and other senescence markers in fat or skin tissue) — not practical for routine use. Accessible proxy measures include: inflammatory biomarkers (hsCRP, IL-6, TNF-α) measured before and after a treatment course, physical function measures (grip strength, walking speed, chair stand test), and potentially epigenetic biological age clocks measured at baseline and after 6–12 months of a protocol. None of these are specific to senolytic effect — they reflect overall health trajectory.
Q4: Are there senolytic clinical trials I can join in 2026?
Yes. ClinicalTrials.gov lists multiple active senolytic trials recruiting participants in the USA — including the SToMP-AD Alzheimer's trial, frailty trials at Mayo Clinic, and others. UK trials are listed on the NIHR Clinical Research Network database. Participating in a trial provides access to senolytics under proper medical supervision, contributes to the evidence base, and typically involves no cost to participants.
Q5: Will senolytics be mainstream medicine in 10 years?
The scientific community is cautiously optimistic. If Unity Biotechnology's UBX1325 achieves FDA approval for diabetic macular oedema, it will be the first FDA-approved senolytic — establishing the regulatory pathway and validating the mechanism in humans. The SToMP-AD results for Alzheimer's, expected 2026–2027, will be closely watched. If dasatinib + quercetin or fisetin produces positive results in adequately powered randomised controlled trials for frailty or age-related disease, the field will accelerate dramatically. The 10-year outlook for senolytic medicine is among the most watched areas in all of clinical research.
Conclusion
Senolytic therapy represents one of the most scientifically grounded approaches in longevity medicine — targeting a specific, well-characterised mechanism of ageing with interventions that have produced dramatic results in preclinical models and early human signals.
In 2026, the evidence base is real but incomplete. Natural senolytics like fisetin are accessible and low-risk, with emerging human evidence. Pharmaceutical senolytics like dasatinib require physician involvement and carry more significant risk profiles. And the definitive human longevity trials that will answer whether senolytics extend healthy human lifespan are underway but not yet complete.
Watch this space. The next five years of senolytic clinical trial data may prove to be among the most consequential in the history of ageing medicine.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Senolytic therapies are largely investigational for longevity purposes. Consult a qualified physician before taking any senolytic compound, particularly prescription medications used off-label.
Comments
Post a Comment